3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Recruiting
2
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Endocrine
2
CNS
2
Genitourinary
1
Conditions
Carcinoma, Renal Cell
21
Parkinson Disease 4, Autosomal Dominant Lewy Body
5
Kidney Neoplasms
5
von Hippel-Lindau Disease
4
Pheochromocytoma
2
Paraganglioma
2
Neoplasm Metastasis
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Ovarian Neoplasms
1
Neuroectodermal Tumors, Primitive
1
Metastatic Castration-Resistant Prostate Cancer
1
Hemangioblastoma
1
Glioblastoma
1
Endometrial Neoplasms
1
Clear-cell metastatic renal cell carcinoma
1
Carcinoma
1
Breast Neoplasms
1
Adenoma, Islet Cell
1
Interventions
Specimen Handling
4
lutetium Lu 177 dotatate
3
gallium Ga 68 dotatate
3
Magnetic Resonance Spectroscopy
3
olaparib
2
cabozantinib
2
belzutifan
2
Temozolomide
2
Nivolumab
2
Fluorodeoxyglucose F18
2
Biopsy
2
6-fluorodopamine
2
3-Iodobenzylguanidine
2
tipifarnib
1
talazoparib
1
spartalizumab
1
pembrolizumab
1
pegfilgrastim
1
lanreotide
1
guadecitabine
1
fluorodopa F 18
1
fludarabine phosphate
1
copper dotatate CU-64
1
atezolizumab
1
Stem Cell Transplantation
1
Phenoxybenzamine
1
Lutetium-177
1
Lutetium
1
Ipilimumab
1
Interleukin-13
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Pheochromocytoma
×
belzutifan
×
1 year
×
Clear all
NCT04924075
2026-05-28
MK-6482-015
Merck Sharp & Dohme LLC
Phase 2
Recruiting
322 enrolled
1 FDA
NCT07167329
2025-09-11
BELIEVE-VHL
AC Camargo Cancer Center
Phase 2
Recruiting
100 enrolled